• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Radiologix losses widen

Article

For the fourth quarter 2003, imaging services provider Radiologix reported service fee revenue of $66 million versus $64 million in the same period of the previous year, a 3.1% increase. But the company noted a net loss of $3 million for the quarter

For the fourth quarter 2003, imaging services provider Radiologix reported service fee revenue of $66 million versus $64 million in the same period of the previous year, a 3.1% increase. But the company noted a net loss of $3 million for the quarter compared with a net loss of $1.6 million for the fourth quarter 2002 and a loss from continuing operations of $1.3 million compared with a continuing operations loss of $585,000 in the fourth quarter of 2002. In fiscal year 2003, service-fee revenue fell 5.6% to $257 million from $272.2 million the previous year. The company incurred a net loss of $8 million for fiscal year 2003 compared with net income of $10.8 million for the year before. For fiscal year 2003, loss from continuing operations was $1.1 million, compared with income from continuing operations of $11.5 million for fiscal 2002.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.